EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

Description

This trial investigates a new drug, EIS-12656, in participants with specified advanced solid tumors carrying pre-specified mutations. The trial consists of a dose escalation part (Phase 1) and a dose expansion part (Phase 2).

Conditions

Advanced Solid Tumor, Homologous Recombination Deficiency, HRR Deficiency

Talk to us

Study Overview

On this page

Study Details

Study overview

This trial investigates a new drug, EIS-12656, in participants with specified advanced solid tumors carrying pre-specified mutations. The trial consists of a dose escalation part (Phase 1) and a dose expansion part (Phase 2).

A Phase 1/2, Open Label Trial to Investigate the Safety, Tolerability, and Preliminary Efficacy of EIS-12656 as Single Agent and in Combination With a Poly-ADP Ribose Polymerase (PARP) Inhibitor or Trastuzumab Deruxtecan (T-DXd), an Antibody Drug Conjugate (ADC), in Participants With Specified Solid Tumors

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

Condition
Advanced Solid Tumor
Intervention / Treatment

-

Contacts and Locations

Houston

MD Anderson Cancer Center, Houston, Texas, United States, 77030

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Recurrent locally advanced or metastatic solid tumors
  • * Homologous recombination deficient mutations
  • * Progressed on at least on prior line of treatment or intolerant to additional effective standard therapy
  • * Measurable disease (RECIST 1.1 Criteria)
  • * Adequate organ and bone marrow function
  • * ECOG Performance Status 0 or 1
  • * Life expectancy \> 3 months
  • * History or evidence of any clinically relevant gastrointestinal disease
  • * Radiation therapy within ≤2 weeks
  • * Significant cardiovascular disease
  • * Uncontrolled, active, symptomatic brain metastases

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Eisbach Bio GmbH,

Timothy Yap, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

2027-12